NEOGENOMICS INC
Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.
On May 2, 2022, Dr. Gina M. Wallar, NeoGenomics, Inc.’s (the “Company”) current President, Pharma Services Division, informed the Company of her intention to resign from her role effective May 27, 2022.
In connection with Dr. Wallar’s departure, Ms. Jennifer Rose will assume interim responsibility for the Pharma Services Division beginning on May 27, 2022.
Extracted from this filing and checked against the source text.
Gina M. Wallar resigned as President, Pharma Services Division at NEOGENOMICS INC.
On May 2, 2022, Dr. Gina M. Wallar, NeoGenomics, Inc.’s (the “Company”) current President, Pharma Services Division, informed the Company of her intention to resign from her role effective May 27, 2022.View on SEC.gov
Jennifer Rose was appointed as Interim President, Pharma Services Division at NEOGENOMICS INC.
In connection with Dr. Wallar’s departure, Ms. Jennifer Rose will assume interim responsibility for the Pharma Services Division beginning on May 27, 2022.View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.